No Surprise: Genentech Urges Shareholders Not To Tender Shares
This article was originally published in The Pink Sheet Daily
Executive Summary
New details from Genentech’s SEC filing show the two companies have been at an impasse regarding the biotech’s valuation since fall 2008.
You may also be interested in...
The Genentech Sales Pitch: Higher Values R Us
Despite a blizzard, Genentech attracts more than 300 Wall Street analysts and investors to hear why Roche’s bid undervalues the biotech.
The Genentech Sales Pitch: Higher Values R Us
Despite a blizzard, Genentech attracts more than 300 Wall Street analysts and investors to hear why Roche’s bid undervalues the biotech.
Roche/Genentech: A Case Study For Future Hostile Offers
It's almost a certainty that five years from now gurus at top-notch B-schools will include the Roche/Genentech saga as a critical case-study in how-or how not-to acquire a partner. They will laud--or criticize--Severin Schwan, Roche's new CEO, for his chutzpah, pending the outcome of the ensuing weeks.